Small-molecule GLP-1 receptor agonist · Fact sheet
Orforglipron
Also known as Foundayo · LY3502970
Orforglipron is the small-molecule GLP-1 medicine in Foundayo, FDA approved for weight management in defined adults. Trials show weight reduction, with gastrointestinal effects and important label warnings; it is not a peptide.
What is Orforglipron?
Orforglipron activates the GLP-1 receptor through a non-peptide molecule. Its evidence and approval are product-specific.
Benefits & claims
Readers often compare its oral formulation, weight effects, appetite effects, and tolerability with semaglutide and tirzepatide. Separate placebo-controlled trials cannot establish a universal ranking.
What the evidence supports
- ATTAIN-1 found greater weight reduction than placebo over 72 weeks in adults with obesity or qualifying overweight.
- Evidence supports the defined weight-management indication; broader disease-prevention claims need their own outcomes studies.
Research areas
- Adult weight management
- Obesity-related metabolic measures
- Type 2 diabetes research
Dosage & frequency
Product-specific label informationFoundayo is an oral GLP-1 receptor agonist with a product-specific adult weight-management titration. Its tablet amounts cannot be substituted for other GLP-1 medicines.
Foundayo
Adults meeting labeled weight-management criteria
- Amount
- 0.8 → 2.5 → 5.5 mg; subsequent eligible steps 9, 14.5 and 17.2 mg
- Frequency
- Once daily; at least 30 days at each step
- Route studied or labeled
- Oral
Maximum 17.2 mg; interacting medicines can restrict or preclude this regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Elimination half-life
- Approximately 29–49 hours.
Formulation differences
- Foundayo is a small molecule, not a peptide; it may be taken with or without food.
Interactions & precautions
- Strong CYP3A4 or OATP1B-related interactions can change the permitted regimen; the label restricts or avoids specified combinations.
What is still unresolved
- It is not an approved general longevity treatment.
Side effects & risks
- Common effects include nausea, constipation, diarrhea, vomiting, abdominal symptoms, headache, fatigue, and hair loss.
- The boxed warning addresses thyroid C-cell tumor risk; the human relevance of receptor-class rodent findings is uncertain. MTC/MEN2 history is a contraindication.
- Warnings include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, allergy, and hypoglycemia with certain medicines.
- Drug interactions, oral-contraceptive effects, pregnancy, retinopathy history, and anesthesia require product-specific clinical assessment.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesPhase 3 weight-management trials support the approved adult indication. Results for weight and metabolic markers should be distinguished from proof of fewer heart attacks, longer life, or every diabetes-related use.
Studies
Phase 3 randomized placebo-controlled trial with 72-week weight outcomes.
Phase 3 trial of orforglipron in adults with obesity or overweight and related conditions.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Appetite: reported experiences
Less appetite with early weight loss
A different commenter described about two weeks of markedly reduced appetite and early weight loss.
Reported use in this account
- Product
- Product described as orforglipron; brand not stated
- Amount
- 0.8 mg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two weeks
Weight was self-reported, with no baseline diet or activity record. The account cannot predict an expected amount of loss.
Read the original accountInitial craving relief later faded
Another commenter initially described reduced cravings and stomach upset with a product claimed to contain orforglipron. A later edit said the effect had become inadequate.
Reported use in this account
- Product
- Unapproved-market tablets claimed to contain orforglipron
- Amount
- 3 mg, then 1.5 mg; later the author said both had become inadequate
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About one month at the initial comment
The author explicitly described an unapproved-market product; contents and strength were unverified. This cannot be transferred to approved Foundayo.
Read the original accountWeight loss with worsening stomach problems
A commenter describing trial participation reported lower appetite and weight loss, but later stomach problems severe enough to consider leaving.
Reported use in this account
- Product
- Trial treatment believed by the commenter to be orforglipron; assignment not verified
- Amount
- 2.5 mg is explicit; other amount numbers in the account have no stated unit
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- One month at the initial amount; total trial duration not stated
Enrollment and treatment assignment were not verified. A participant's belief about receiving active drug is not proof of allocation.
Read the original accountWeight: reported experiences
Less appetite with early weight loss
A different commenter described about two weeks of markedly reduced appetite and early weight loss.
Reported use in this account
- Product
- Product described as orforglipron; brand not stated
- Amount
- 0.8 mg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two weeks
Weight was self-reported, with no baseline diet or activity record. The account cannot predict an expected amount of loss.
Read the original accountWeight loss with worsening stomach problems
A commenter describing trial participation reported lower appetite and weight loss, but later stomach problems severe enough to consider leaving.
Reported use in this account
- Product
- Trial treatment believed by the commenter to be orforglipron; assignment not verified
- Amount
- 2.5 mg is explicit; other amount numbers in the account have no stated unit
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- One month at the initial amount; total trial duration not stated
Enrollment and treatment assignment were not verified. A participant's belief about receiving active drug is not proof of allocation.
Read the original accountDigestion: reported experiences
Nausea returned after initial relief
A new user reported nausea through much of the first day. A reply initially described feeling better the next day, then corrected that nausea had returned later.
Reported use in this account
- Product
- Product described as orforglipron; brand and strength not stated by this commenter
- Amount
- Not specified clearly
- Frequency
- Two successive mornings described; longer-term frequency not stated
- Route
- Not specified clearly
- Duration
- First two days
The short observation does not establish lasting tolerability, and the product and medical history were not independently verified.
Read the original accountInitial craving relief later faded
Another commenter initially described reduced cravings and stomach upset with a product claimed to contain orforglipron. A later edit said the effect had become inadequate.
Reported use in this account
- Product
- Unapproved-market tablets claimed to contain orforglipron
- Amount
- 3 mg, then 1.5 mg; later the author said both had become inadequate
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About one month at the initial comment
The author explicitly described an unapproved-market product; contents and strength were unverified. This cannot be transferred to approved Foundayo.
Read the original accountWeight loss with worsening stomach problems
A commenter describing trial participation reported lower appetite and weight loss, but later stomach problems severe enough to consider leaving.
Reported use in this account
- Product
- Trial treatment believed by the commenter to be orforglipron; assignment not verified
- Amount
- 2.5 mg is explicit; other amount numbers in the account have no stated unit
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- One month at the initial amount; total trial duration not stated
Enrollment and treatment assignment were not verified. A participant's belief about receiving active drug is not proof of allocation.
Read the original accountNo clear change: reported experiences
Initial craving relief later faded
Another commenter initially described reduced cravings and stomach upset with a product claimed to contain orforglipron. A later edit said the effect had become inadequate.
Reported use in this account
- Product
- Unapproved-market tablets claimed to contain orforglipron
- Amount
- 3 mg, then 1.5 mg; later the author said both had become inadequate
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About one month at the initial comment
The author explicitly described an unapproved-market product; contents and strength were unverified. This cannot be transferred to approved Foundayo.
Read the original accountApproval status
FDA approved Foundayo on April 1, 2026, for reducing excess weight and maintaining weight reduction in adults with obesity or overweight with at least one weight-related condition, alongside diet and physical activity.
Approved uses
- Foundayo: long-term weight reduction and maintenance in adults meeting the label’s obesity or overweight criteria
Foundayo FDA approved in 2026
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Longer-term outcomes in broader clinical use
- Direct comparisons for specific patient-relevant outcomes
- Uncommon harms beyond trial follow-up
Summary
Foundayo is approved for a defined adult weight-management use. Its product-specific risks and warnings remain central.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: Foundayo prescribing information
Approved adult weight indication, contraindications, warnings, interactions, and clinical results.
- journalATTAIN-1: orforglipron for obesity treatment
Phase 3 randomized placebo-controlled trial with 72-week weight outcomes.
- clinical trialsATTAIN-1 registry
Phase 3 trial of orforglipron in adults with obesity or overweight and related conditions.